1789 — ScinoPharm Taiwan Share Price
0.000.00%
Last trade - 00:00- TWD14.83bn
- TWD11.34bn
- TWD3.41bn
- 67
- 25
- 63
- 53
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.39 | ||
| Price to Tang. Book | 1.4 | ||
| Price to Free Cashflow | 31.16 | ||
| Price to Sales | 4.31 | ||
| EV to EBITDA | 13.83 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 2.86% | ||
| Return on Equity | 3.25% | ||
| Operating Margin | 9.39% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | TWDm | 3,082.93 | 2,762.34 | 3,264.05 | 3,186.08 | 3,406.28 | 3,550 | n/a | 3.32% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +29.4 | -13.74 | +45.58 | -18.62 | +19.64 | -12.44 | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ScinoPharm Taiwan Ltd is a Taiwan-based company mainly engaged in the research, development, manufacture and sale of active pharmaceutical ingredients. The main products include active pharmaceutical ingredients, protein drugs, oligonucleotides, peptides, injection preparations, new small molecule drugs and other chemical raw materials. The Company is also engaged in the provision of consulting and biotechnology services for related products, the international trading of products, as well as the provision of customized full-process services such as chemical molecular component synthesis, process development and commercial mass production. The Company operates within the domestic market and to overseas markets, including the Americas, Europe, Australia and Asia.
Directors
- Chih-Hsien Lo CHM (64)
- Li-An Lu GMG
- Li-Chiao Chang DGM
- Katy Cheng DGM
- Ling-Hsiao Lian DGM
- Ching-Wen Lin DGM
- Chih-Ching Hsu OTH
- Jia-Horng Guo DRC
- Po-Ming Hou DRC
- Ming-Chuan Hsieh DRC
- Shiow-Ling Kao DRC
- Fu-Jung Lai DRC
- Chiou-Ru Shih DRC
- Kuo-Hsi Wang DRC
- Tsung-Pin Wu DRC
- Ya-Po Yang DRC
- Jingyuan Zheng DRC
- Wen-Chang Chang IND
- Li-Tzong Chen IND
- Mingxian Li IND
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 11th, 1997
- Public Since
- October 29th, 2010
- No. of Employees
- 1,010
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Taiwan Stock Exchange
- Shares in Issue
- 790,739,000
- Address
- No. 1, Nan-Ke 8th Road, TAINAN, 741
- Web
- https://www.scinopharm.com.tw/
- Phone
- +886 65052888
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for 1789
ScinoPharm Taiwan Ltd Annual Shareholders Meeting
Q2 2025 ScinoPharm Taiwan Ltd Earnings Release
Similar to 1789
Adimmune
Taiwan Stock Exchange
Bora Pharmaceuticals Co
Taiwan Stock Exchange
BRIM Biotechnology
Taiwan Stock Exchange
Caliway Biopharmaceuticals Co
Taiwan Stock Exchange
Cenra
Taiwan Stock Exchange
FAQ
What is the ScinoPharm Taiwan share price?
As of Today at 23:07 UTC, shares in ScinoPharm Taiwan are trading at TWD18.55. This share price information is delayed by 15 minutes.
How has the ScinoPharm Taiwan share price performed this year?
Shares in ScinoPharm Taiwan last closed at TWD18.55 and the price had moved by -34.22% over the past 365 days. In terms of relative price strength the ScinoPharm Taiwan share price has underperformed the FTSE Developed Asia Pacific Index by -33.47% over the past year.
What are the analyst and broker recommendations for ScinoPharm Taiwan?
The overall consensus recommendation for ScinoPharm Taiwan is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the ScinoPharm Taiwan dividend yield?
The ScinoPharm Taiwan dividend yield is 1.89% based on the trailing twelve month period.
Does ScinoPharm Taiwan pay a dividend?
Last year, ScinoPharm Taiwan paid a total dividend of TWD0.35, and it currently has a trailing dividend yield of 1.89%. We do not have any data on when ScinoPharm Taiwan is to next pay dividends.
When does ScinoPharm Taiwan next pay dividends?
We do not have data on when ScinoPharm Taiwan is to next pay dividends. The historic dividend yield on ScinoPharm Taiwan shares is currently 1.89%.
How do I buy ScinoPharm Taiwan shares?
To buy shares in ScinoPharm Taiwan you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of ScinoPharm Taiwan?
As of the previous close price of TWD18.55, shares in ScinoPharm Taiwan had a market capitalisation of TWD14.83bn.
Where are ScinoPharm Taiwan shares listed?
Here are the trading details for ScinoPharm Taiwan:
- Country of listing: Taiwan
- Exchange: TAI
- Ticker Symbol: 1789
What kind of share is ScinoPharm Taiwan?
Based on an overall assessment of its quality, value and momentum ScinoPharm Taiwan is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a ScinoPharm Taiwan share price forecast for 2025?
The analyst consensus target price for shares in ScinoPharm Taiwan is TWD26.71. That is 44% above the last closing price of TWD18.55.
Analysts covering ScinoPharm Taiwan currently have a consensus Earnings Per Share (EPS) forecast of TWD0.38 for the next financial year.
Find out moreWhat is the trend in the ScinoPharm Taiwan share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ScinoPharm Taiwan. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -18.94%.
As of the last closing price of TWD18.55, shares in ScinoPharm Taiwan were trading -21.63% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the ScinoPharm Taiwan PE Ratio?
The ScinoPharm Taiwan PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at TWD18.55.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of ScinoPharm Taiwan?
ScinoPharm Taiwan's management team is headed by:
- Chih-Hsien Lo - CHM
- Li-An Lu - GMG
- Li-Chiao Chang - DGM
- Katy Cheng - DGM
- Ling-Hsiao Lian - DGM
- Ching-Wen Lin - DGM
- Chih-Ching Hsu - OTH
- Jia-Horng Guo - DRC
- Po-Ming Hou - DRC
- Ming-Chuan Hsieh - DRC
- Shiow-Ling Kao - DRC
- Fu-Jung Lai - DRC
- Chiou-Ru Shih - DRC
- Kuo-Hsi Wang - DRC
- Tsung-Pin Wu - DRC
- Ya-Po Yang - DRC
- Jingyuan Zheng - DRC
- Wen-Chang Chang - IND
- Li-Tzong Chen - IND
- Mingxian Li - IND